Literature DB >> 21471731

Highly conserved influenza A sequences as T cell epitopes-based vaccine targets to address the viral variability.

Paul Thiamjoo Tan1, Asif M Khan, J Thomas August.   

Abstract

Vaccines are the only proven effective method for prevention of human infectious diseases. Almost all traditional vaccines require activating immunological memory B cells to secrete neutralizing antibodies against invading pathogens. The complication with influenza viruses is the high viral mutation rate that results in immune escape through modification of the B cell epitopes. Studies of T-cell immunity to influenza infection provide an alternative vaccine strategy based on highly conserved T-cell epitopes. In this review, we discuss the importance of T cell-mediated immunity in influenza infection and the need for a targeted vaccine approach focused on highly conserved T-cell epitopes to mitigate immune escape. We propose 15 highly conserved pan-influenza sequences as possible T cell epitopes-based vaccine targets for broad protection and lasting immunity against variant influenza strains.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21471731     DOI: 10.4161/hv.7.4.13845

Source DB:  PubMed          Journal:  Hum Vaccin        ISSN: 1554-8600


  17 in total

1.  Cold-adapted pandemic 2009 H1N1 influenza virus live vaccine elicits cross-reactive immune responses against seasonal and H5 influenza A viruses.

Authors:  Yo Han Jang; Young Ho Byun; Yoon Jae Lee; Yun Ha Lee; Kwang-Hee Lee; Baik Lin Seong
Journal:  J Virol       Date:  2012-03-21       Impact factor: 5.103

2.  Structural and Biochemical Analyses of Swine Major Histocompatibility Complex Class I Complexes and Prediction of the Epitope Map of Important Influenza A Virus Strains.

Authors:  Shuhua Fan; Yanan Wu; Song Wang; Zhenbao Wang; Bo Jiang; Yanjie Liu; Ruiying Liang; Wenzhong Zhou; Nianzhi Zhang; Chun Xia
Journal:  J Virol       Date:  2016-07-11       Impact factor: 5.103

Review 3.  The weight of obesity on the human immune response to vaccination.

Authors:  Scott D Painter; Inna G Ovsyannikova; Gregory A Poland
Journal:  Vaccine       Date:  2015-07-08       Impact factor: 3.641

Review 4.  The prospects and challenges of universal vaccines for influenza.

Authors:  Kanta Subbarao; Yumiko Matsuoka
Journal:  Trends Microbiol       Date:  2013-05-17       Impact factor: 17.079

5.  HLA targeting efficiency correlates with human T-cell response magnitude and with mortality from influenza A infection.

Authors:  Tomer Hertz; Christine M Oshansky; Philippa L Roddam; John P DeVincenzo; Miguela A Caniza; Nebojsa Jojic; Simon Mallal; Elizabeth Phillips; Ian James; M Elizabeth Halloran; Paul G Thomas; Lawrence Corey
Journal:  Proc Natl Acad Sci U S A       Date:  2013-07-22       Impact factor: 11.205

6.  LEAPS therapeutic vaccines as antigen specific suppressors of inflammation in infectious and autoimmune diseases.

Authors:  Daniel H Zimmerman; Harold Steiner; Roy Carmabula; Eyal Talor; Ken S Rosenthal
Journal:  J Vaccines Vaccin       Date:  2012-09-20

Review 7.  Cross-protective immune responses elicited by live attenuated influenza vaccines.

Authors:  Yo Han Jang; Baik Lin Seong
Journal:  Yonsei Med J       Date:  2013-03-01       Impact factor: 2.759

8.  Role of T-cell epitope-based vaccine in prophylactic and therapeutic applications.

Authors:  James S Testa; Ramila Philip
Journal:  Future Virol       Date:  2012-11-01       Impact factor: 1.831

9.  Analysis of the affinity of influenza A virus protein epitopes for swine MHC I by a modified in vitro refolding method indicated cross-reactivity between swine and human MHC I specificities.

Authors:  Shuhua Fan; Yongli Wang; Xian Wang; Li Huang; Yunxia Zhang; Xiaomeng Liu; Wenshuai Zhu
Journal:  Immunogenetics       Date:  2018-07-10       Impact factor: 2.846

10.  MHC class I-presented T cell epitopes identified by immunoproteomics analysis are targets for a cross reactive influenza-specific T cell response.

Authors:  James S Testa; Vivekananda Shetty; Julie Hafner; Zacharie Nickens; Shivali Kamal; Gomathinayagam Sinnathamby; Ramila Philip
Journal:  PLoS One       Date:  2012-11-07       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.